The report, which was commissioned by Nutra Pharma, focuses on the company's current drug development initiatives, including the company's leading drug candidates for the treatment of Multiple Sclerosis (MS), HIV, Adrenomyeloneuropathy (AMN), and Rheumatoid Arthritis (RA) as well as the company's recent launch of Cobroxin for the treatment of chronic pain, the Company noted in a release.
Report Information:
http://www.cohenresearch.com/reports/nphc_10-21-09.pdf
((Comments on this story may be sent to health@closeupmedia.com))

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index